메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Therme Group Selected by Singapore Government to Build As…

Marina South Coast to be transformed into next-generation urban infrastructure, advancing wellbeing at scale, the Group's inaugural destination in Asia. SINGAPORE, Nov. 4, 2025 -- Therme Group, the leading global developer and operator of next-generation wellbeing destinations, today announced that it will be developing a S$1 billion state-of-the-art wellbeing oasis in Singapore, following the award of the Concept and Price Revenue Tender for a Wellness Attraction at the Marina South Coastal site by the Singapore Tourism Board (STB). This marks Therme Group's first foray into Singapore
- 김갑성 기자
- 2025-11-04 09:42
ICP DAS-BMP Redefines Medical Material Performance with Low-…

HSINCHU, Nov. 4, 2025 -- ICP DAS-BMP (Biomedical Polymers), a Taiwan-based manufacturer and supplier of medical-grade TPU (thermoplastic polyurethane), is pleased to announce its participation in COMPAMED 2025, taking place from November 17 to 20 at Messe Düsseldorf, Germany. Visitors can find the ICP DAS-BMP team at Hall 8b, Booth C09-4. The highlight of this year's exhibit will be two TPU innovations designed to address critical needs in medical device manufacturing: the Low-Migration Series and the Low-Friction Series. The low-migration Arothane™ ARP-B20
- 김갑성 기자
- 2025-11-04 08:45
ICP DAS-BMP, 컴파메드 2025에서 저이행성•저마찰 TPU로 의료용 소재 성능 재정의

신주 2025년 11월 4일 -- 대만의 의료용 열가소성 폴리우레탄(TPU) 제조•공급업체인 ICP DAS-BMP가 11월 17일부터 20일까지 독일 뒤셀도르프 메세 전시장에서 열리는 컴파메드 2025(COMPAMED 2025)에 참가한다고 발표했다. 방문객들은 홀 8b, C09-4 부스에서 ICP DAS-BMP 팀을 만날 수 있다. 올해 전시회의 하이라이트 중 하나는 의료기기 제조의 핵심 요구사항을 해결하기 위해 설계된 두 가지 TPU 혁신 제품인 Low-Migration 시리즈와 Low-Friction 시리즈다. 저이행성 Arothane™ ARP-B20 TPU는 ISO 10993을 준수하며 최대 90일간의 이식에 적합하다. 가공 중 첨가제 이행을 최소화해 카테터의 유통기한 동안 매끄러운 표면을 유지하는 동시에 유연하고 맞춤화된 설계를 위한 15가지 색상 옵션을 제공한다. 또 다른 핵심은 첫 선을 보이는 Low-Friction 시리즈로, 본질적으로 매끄러운 표면으로 설계되어 추가 코팅이나 후처리 공정이 필요하지 않다. Low-Friction 시리즈는 TPU로만 구성되어 과불화화합물(PFAS
- 김갑성 기자
- 2025-11-04 08:45
존슨앤드존슨, APHRS 및 JPHRS에서 다양한 임상시험과 실사용 시험을 통해 거둔 펄스장 절…

시술 부위 세척 과정을 최적화하고 일관된 시술 결과를 기대할 수 있는 새로운 안전성, 유효성 및 시술 절차 개선 데이터를 중점적으로 다루는 구두 발표 시간도 마련 요코하마, 2025년 11월 4일 -- 심장 부정맥 치료 분야의 세계적인 선두 기업1인 존슨앤드존슨 메드테크(Johnson & Johnson MedTech)가 오늘 심방세동(AF) 치료 목적의 펄스장 절제술(PFA)에 완전 통합형 베리펄스(VARIPULSE™) 플랫폼을 이용해 확보한 새로운 임상 및 실사용 데이터를 아시아ㆍ태평양 부정맥학회(Asia Pacific Heart Rhythm Society, APHRS) 및 일본 부정맥학회(Japanese Heart Rhythm Society, JHRS)의 공동 연례 회의에서 공개할 예정이라고 발표했다. 이 연례 회의는 2025년 11월 12일~15일 일본 요코하마에서 개최된다. 이 완전 통합형 플랫폼은 베리펄스 카테터(VARIPULSE™ Catheter), 트루펄스 제너레이터(TRUPULSE™ Generator), 그리고 카토 3 매핑 시스템 베리펄스 소프트웨어(CARTO™ 3 Mapping System V
- 김갑성 기자
- 2025-11-04 03:56
CQ Medical® Appoints Michael Galbus as Chief Executive Offic…

AVONDALE, Pa., Nov. 4, 2025 -- CQ Medical is pleased to announce the appointment of Michael Galbus as Chief Executive Officer. Michael previously served as Chief Operating Officer, where he played a key role in enhancing operational performance, advancing the company's growth strategy, and building trust across the executive team while championing the growth and development of his team members. A cancer survivor, Michael has a deeply personal connection to CQ Medical's mission of improving care and outcomes for patients and clinicians. He is recognized for his collaborative lea
- 김갑성 기자
- 2025-11-04 02:00
CARsgen Announces Positive Clinical Data for Allogeneic CAR…

SHANGHAI, Nov. 3, 2025 -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces clinical data for CT0596, an allogeneic BCMA-targeting CAR-T product candidate developed on its proprietary THANK-u Plus™ platform for relapsed/refractory multiple myeloma (R/R MM), and for CT1190B, an allogeneic CD19/CD20-targeting CAR-T product candidate for relapsed/refractory non-Hodgkin's lymphoma (R/R NHL). The data showed that both allogeneic CAR-T products demonstrated initially favorable safety profiles and encouragi
- 김갑성 기자
- 2025-11-03 22:15
EmeTerm Wristband Significantly Reduces Postoperative Nau…

VANCOUVER, BC, Nov. 3, 2025 -- WAT Medical Enterprise Ltd. proudly announced the publication of a groundbreaking clinical trial in The Journal of Bone & Joint Surgery (JBJS) which demonstrates the significant benefits of the EmeTerm wristband in reducing postoperative nausea and vomiting (PONV) in patients undergoing total hip or knee arthroplasty (THA/TKA) under spinal anesthesia. The study aimed to evaluate whether the addition of the EmeTerm wristband to conventional antiemetic therapy could enhance prevention of PONV after orthopedic surgeries. This randomized controlled study
- 김갑성 기자
- 2025-11-03 22:00
Sanyou Bio and Shanghai ZJ Bio-Tech Sign Strategic Coope…

SHANGHAI, Nov. 3, 2025 -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") and Shanghai ZJ Bio-Tech technology Co., Ltd. (hereinafter referred to as "Shanghai ZJ Bio-Tech") jointly announced the official signing of a strategic cooperation agreement on the automated development of innovative biologics. This collaboration aims to jointly tackle drug development bottlenecks by introducing automation technology to significantly shorten the R&D cycle for innovative drugs. According to the agreement, Sanyou Bio will upgrade the
- 김갑성 기자
- 2025-11-03 22:00
Samsung Biologics completes spin-off to strengthen its foc…

Spin-off finalized within five months following board resolution Proposal approved in shareholders' meeting with 99.9% support Company to reaffirm its identity as a pure-play CDMO INCHEON, South Korea, Nov. 3, 2025 -- Samsung Biologics (KRX: 207940.KS) today announced the completion of its spin-off of Samsung Bioepis, reinforcing its strategic focus and business specialization as a leading pure-play Contract Development and Manufacturing Organization (CDMO). Following approval by its Board of Directors, Samsung Biologics separated its investment an
- 김갑성 기자
- 2025-11-03 20:00
TCT 2025 | Robot-Assisted PCI Enters a New Era: Results of the…

SHANGHAI, Nov. 3, 2025 -- The 37th Annual Transcatheter Cardiovascular Therapeutics (TCT2025) symposium was held grandly in San Francisco, USA, attracting widespread attention from the global cardiovascular community. On the morning of October 28th (local time), during the "Innovation Session: Robotics and AI-Enhanced Interventions," Dr. Wang Rui, representing the team of Academician Ge Junbo from Zhongshan Hospital Affiliated to Fudan University, presented to the world for the first time the safety and efficacy data from the multicenter randomized controlled trial of China's indepe
- 김갑성 기자
- 2025-11-03 18:04

이전

41 42 43 44 45 46 47 48 49 50

많이 본 기사

최근기사

2025-12-11_THU

2025-12-10_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 11일 04시 20분